EGFR and non-small cell lung carcinoma: In EGFR-mutant NSCLC, 3 years of adjuvant osimertinib plus or minus chemotherapy versus placebo had a profound effect on DFS (HR = 0.17) with low comparative LR rates, at 11% versus 46%.